Stocktoria
Relay Therapeutics, Inc. RLAY
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-07-16
Relay Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M |
| Operating income | -$302.7M | -$372.5M | -$373.0M | -$299.3M | -$364.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$276.5M | -$337.7M | -$342.0M | -$290.5M | -$363.9M |
| EPS (diluted) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
| Operating cash flow | -$235.5M | -$249.1M | -$300.3M | -$229.5M | -$74.4M |
| Free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M | -$77.9M |
| Cash & equivalents | $84.0M | $124.3M | $143.7M | $151.8M | $280.1M |
| Total assets | $621.3M | $871.3M | $844.0M | $1.1B | $1.0B |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M | $110.6M |
| Shareholders' equity | $567.1M | $777.8M | $752.0M | $950.2M | $897.8M |
Source: SEC EDGAR filings · CIK 0001812364 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.